The Sandur Manganese & Iron Ores Limited has approved the incorporation of a new wholly-owned subsidiary, ‘Royal Sandur MedTech Private Limited’. This strategic move signals the company’s intention to venture into new lines of business, specifically focusing on the manufacturing and distribution of medical devices and consumables. The subsidiary is being established with an initial investment of ₹1,00,00,000 through the subscription of 10,00,000 equity shares.
Strategic Expansion into Healthcare Sector
The Sandur Manganese & Iron Ores Limited announced today, September 17, 2026, that its Board of Directors has approved the incorporation of a new wholly-owned subsidiary. This significant step is part of the company’s strategy to explore and venture into new business areas. The new entity will be named ‘Royal Sandur MedTech Private Limited’.
Focus on Medical Devices and Consumables
The newly approved subsidiary, Royal Sandur MedTech Private Limited, is slated to engage in the business of manufacturing, processing, assembling, marketing, and distribution of medical devices and healthcare consumables. This includes a broad range of products such as surgical products and diagnostic tools. The company sees this as a strategic diversification effort to tap into the growing healthcare market.
Investment and Ownership Structure
The incorporation of Royal Sandur MedTech Private Limited will be facilitated through a cash consideration. The Sandur Manganese & Iron Ores Limited will subscribe to 10,00,000 equity shares of ₹10/- each, aggregating to a total investment of ₹1,00,00,000. This investment ensures that the subsidiary will be wholly owned, with The Sandur Manganese & Iron Ores Limited holding 100% shareholding.
Source: BSE
